| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2012: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2011: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2010: ¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
|
|---|
| Research Abstract |
Up-regulation of aldo-keto reductase (AKR) 1B10 was provoked with resistance development of human colon cancer HT29 cells toward doxorubicin or mitomycin C. In addition, results in several experiments with the two resistant cancer cellssuggest that the high AKR1B10 expression contributes tomechanism(s) of the chemoresistance through facilitating the reductase activity toward the drugs and antioxidant activity. Furthermore, overexpression and inhibition of the enzyme in the non-resistant cells decreased and increased, respectively, susceptibility to cytotoxic effects of the drugs, raising the possibility that AKR1B10 is a predominant factor involved in gain of colon cancer chemoresistance.
|
